Last reviewed 2026-05-26 · How we verify

Any Fixed Combination Therapy

Allergan · Phase 2 active Small molecule Under review

Any Fixed Combination Therapy is a Small molecule drug developed by Allergan. It is currently in Phase 2 development for Various conditions.

This fixed combination therapy works by combining multiple drugs to treat various conditions.

Any Fixed Combination Therapy, also known as ACORVIO, is a small molecule inhibitor that targets Lanosterol 14-alpha demethylase, specifically inhibiting the cytochrome P450 51 enzyme. It has been studied in various clinical trials for conditions such as HIV-1-infection, Advanced Solid Tumor, Colorectal Cancer, Type 2 Diabetes Mellitus, and Grade II and III Acute Lateral Ankle Ligament Injuries.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Any Fixed Combination Therapy
Sponsor	Allergan
Modality	Small molecule
Phase	Phase 2

Mechanism of action

The exact mechanism of action is unknown, but it is believed to work by targeting multiple pathways to achieve therapeutic effects.

Approved indications

Various conditions

Common side effects

Unknown

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Any Fixed Combination Therapy CI brief — competitive landscape report
Any Fixed Combination Therapy updates RSS · CI watch RSS
Allergan portfolio CI

Frequently asked questions about Any Fixed Combination Therapy

What is Any Fixed Combination Therapy?

Any Fixed Combination Therapy is a Small molecule drug developed by Allergan, indicated for Various conditions.

How does Any Fixed Combination Therapy work?

This fixed combination therapy works by combining multiple drugs to treat various conditions.

What is Any Fixed Combination Therapy used for?

Any Fixed Combination Therapy is indicated for Various conditions.

Who makes Any Fixed Combination Therapy?

Any Fixed Combination Therapy is developed by Allergan (see full Allergan pipeline at /company/allergan).

What development phase is Any Fixed Combination Therapy in?

Any Fixed Combination Therapy is in Phase 2.

What are the side effects of Any Fixed Combination Therapy?

Common side effects of Any Fixed Combination Therapy include Unknown.

Manufacturer: Allergan — full pipeline
Indication: Drugs for Various conditions

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing